
Check-Cap Ltd. (CHEK) Stock Ticker
Market factors today
Unlock the full CHEK picture
About Check-Cap Ltd.
Check-Cap Ltd. is an Israeli medical diagnostics company currently in the clinical development phase. It is dedicated to advancing a novel capsule-based screening method that employs ultra-low-dose X-rays. This technology is designed to thoroughly examine the internal surface of the colon, aiming to identify precancerous polyps and other structural irregularities. The company's primary offering, the C-Scan system, is composed of three integral parts: the C-Scan Cap, an ingestible X-ray scanning capsule for detecting suspected polyps; the C-Scan Track, a disposable unit that adheres to the patient's back via biocompatible adhesive patches; and the C-Scan View software. This client/server application enables the download of procedural data from the C-Scan Track, performs detailed analysis, and generates comprehensive reports. Check-Cap Ltd. was founded in 2004 and operates from its headquarters in Isfiya, Israel.
CHEK stock facts
| Ticker symbol | CHEK |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |
| Market cap | $10.9M |
| CEO | David Lontini |
| Employees | 85 |
| Headquarters | Isfiya, IL |
| IPO date | 2015-03-04 |
| Website | www.check-cap.com |
What you can see for CHEK on Tickr
Live CHEK price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the CHEK report.
Rankings
FAQ
What is the ticker symbol for Check-Cap Ltd.?
The ticker symbol for Check-Cap Ltd. is CHEK, listed on the NASDAQ Capital Market.
What is CHEK?
Check-Cap Ltd. is an Israeli medical diagnostics company currently in the clinical development phase. It is dedicated to advancing a novel capsule-based screening method that employs ultra-low-dose X-rays. This technology is designed to thoroughly examine the internal surface of the colon, aiming to identify precancerous polyps and other structural irregularities. The company's primary offering,…